

Correlation of PSA Density to Prostate Cancer Based on Prostate Volume by 3.0 T MRI

Rulon L. Hardman^{1*}, Yuanyuan Liang^{2,3}, Steve Ware¹, Adam J. Jung, Qi Peng¹,
Fadi El-Merhi¹, Yumin Chen², Ian M. Thompson³

¹Department of Radiology, University of Texas Health Science
Center at San Antonio, San Antonio, USA

²Department of Epidemiology and Biostatistics, University of Texas Health Science
Center at San Antonio, San Antonio, USA

³Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, USA
E-mail: Hardmanr@uthscsa.edu

Received March 1, 2011; revised May 13, 2011; accepted June 20, 2011

Abstract

Purpose: Prostate specific antigen levels can be normalized by the prostate volume to give a prostate specific antigen density (PSAd). Magnetic resonance imaging (MRI) can more accurately determine prostate zonal anatomy and prostate volumes compared to transrectal ultrasound, and hence may lead to more accurate PSAd measurements. **Methods:** Imaging and pathology of men undergoing prostate MRI from April 2007 to May 2009 were reviewed in this retrospective study. 73 patients were included for analysis, of which 45 had prostate cancer and 28 did not have cancer. Total, transitional zone, and peripheral zone values were determined by ultrasound prolate ellipse, MRI prolate ellipse, and MRI segmentation methods. **Results:** The study population showed an average PSA of 6.3 ng/mL, with the control mean PSA (8.8 ng/mL) being greater than the cancer group (5.3 ng/mL). Transrectal ultrasound underestimated the prostate volume (mean 27.7 mL versus MRI volume of 38.3 mL, $p \leq 0.001$). No difference was seen between cancer and control populations using PSAd. PSAd correctly categorized low (Gleason < 7) and high-grade cancers (Gleason ≥ 7) in patients with malignancy. **Conclusion:** Transrectal ultrasound underestimates prostate volumes and hence is inaccurate in calculating PSAd. MRI more accurately depicts PSAd, however PSAd is unable to differentiate between patients with cancer and benign disease such as BPH or prostatitis.

Keywords: Magnetic Resonance Imaging, Prostatic Neoplasm, Prostate-Specific Antigen

1. Introduction

Prostate specific antigen (PSA) is a commonly used tumor marker in screening patients for prostate cancer risk [1,2]. A typical cut off value of 4.0 ng/mL indicates an abnormal result [1]. However, the test is not specific as other pathologies including inflammation and benign prostatic hyperplasia (BPH) can increase PSA [1]. Current PSA recommendations lead to significant overtreatment and associated morbidity from unnecessary biopsies, as well as psychological stress in the patient. For these reasons, many have advocated normalizing the PSA by the volume of the prostate gland, yielding a PSA density (PSAd) [3-5].

The use of PSAd for cancer diagnosis is controversial with studies both confirming and refuting the use of

PSAd [6-10]. In an effort to further improve the specificity, PSAd can be based on the transitional zone of the prostate, the region of the prostate most affected by BPH changes, however, these results remain controversial [6-8, 11]. A possible explanation for the lack of added specificity of PSAd may be that the volume of the prostate is typically determined by transrectal ultrasound, which is inaccurate in determining prostate volume [12,13]. Prostate MRI can accurately depict prostate zonal anatomy. MRI has been shown to be useful in differentiating high-grade and low-grade cancer, but groups have not shown their results for sensitivity for detecting cancer [14-17]. We undertook the study to determine the accuracy of PSAd, calculated using MRI and transrectal ultrasound, in characterizing benign from malignant disease in a population with persistently elevated PSA.

2. Methods

Investigational Review Board (IRB) consent was obtained and Health Insurance Portability and Accountability Act (HIPAA) and confidentiality practices were followed.

Patients were referred for prostate MRI for staging, cancer follow-up, or being high risk for prostate cancer (based on elevated PSA or palpable nodule). Patients were excluded from analysis if they had any prostate volume altering therapies, including 5-alpha inhibitor treatment, brachytherapy or cryoablation. Patients were also excluded if pathologic biopsy or prostatectomy results could not be obtained.

All patients underwent a prostate MRI on a 3.0 Tesla platform (Achieva, Philips Healthcare, Best, Netherlands) using combined cardiac phase array coil (Philips Healthcare, Best, Netherlands), and endorectal coil (BPX-30, Medrad, Pittsburgh, PA). High resolution T2W protocol was performed by a fast spin-echo sequence covering the prostate and seminal vesicles. The scan parameters were: TR/TE (3000 - 4000)/110 ms, echo train length = 20, slice thickness = 3 mm, interslice gap = 0 mm, field of view = $14 \times 14 \text{ cm}^2$, matrix 500×550 , fold-over direction left to right, 3 excitations, and in-plane resolution of $0.3 \times 0.3 \text{ mm}^2$. High-resolution T2W sequences were used for volume measurement as they depict the prostate in the greatest detail.

Axial and sagittal images were analyzed to determine the prostate volume by prolate ellipse and segmentation methods (**Figure 1**). The anterior-posterior, cranial-caudal, and transverse dimensions were taken of the total prostate and transitional zone at the widest portion of the prostate. The prostate volume was then determined using Equation (1). The volume of an object may also be approached by taking thin segments through the object and

adding the areas of each segment, also known as segmentation. Segmentation was performed by drawing a region of interest around the total prostate and transitional zone on each axial image slice. The sum of the areas was then multiplied by the slice thickness (3 mm) and the segmented volumes were summed to determine the total prostate volume.

$$\text{Prostate Volume} = AP \times CC \times Trans \times 0.52 \quad (1)$$

Patient records were reviewed to determine pathology from pre- and post- MRI biopsies and prostatectomy. Prostate volumes based on digital rectal exam and transrectal ultrasound was also recorded when available and recorded. Data was only available on 52 out of the 92 men. The maximum time from ultrasound to MRI measurement was 6 months. Three urologists (26 years, 13 years, and 6 years experience) at our institution performed all biopsies and ultrasound volume calculations using a standard prostate ellipse methodology. Transrectal ultrasound measurements were performed using the Hawk 2102 XDI Ultrasound Scanner (B-K Medical, Herlev, Denmark). A single radiologist (4 years experience) performed all MRI calculations. The most recent PSA prior to the prostate MRI was used for PSA density calculations. The PSA density was determined by dividing the PSA by the ultrasound volume, prolate ellipse MRI volume, and segmentation MRI volume. Peripheral zone volume was determined by subtracting the transitional zone volume from the total prostate volume.

Statistical Methods

Seven different PSA densities were calculated by dividing the PSA by various prostate volumes (total prostate volume, transitional zone volume, or peripheral zone volume) using different methods (ultrasound, prolate ellipse or segmentation). Areas underneath the receiver-




Figure 1. Prostate volume calculation. Image (a) and (b) show the measurements for the prolate ellipse method. The black line demarcates the total prostate. The white line shows the central gland. Image (c) shows the segmentation curves placed around the prostate margins. The volume is calculated by adding each slice area.

operating characteristic (ROC) curve (AUCs) were calculated for PSA and various PSAdS using the Wilcoxon statistic, and nonparametric U-statistic method was used performing the differences between AUCs [18] with appropriate Bonferroni adjustment. Comparison was conducted between the patients with aggressive cancer and the patients with no cancer or low-grade cancer using a Mann-Whitney U test.

All statistical tests were performed at a significance level of 0.05 (two sided) and conducted using SAS (Version 9.2, Cary, NC: SAS Institute Inc.).

3. Results

Patient demographics are summarized in **Table 1**. A total of 92 patients underwent prostate MRI from April 2007 to May 2009. 73 patients were included for analysis using our inclusion criteria. 16 patients underwent prostatectomy with 57 men only having pathology based on TRUS biopsy. 45 patients had pathologic evidence of prostate cancer. The average PSA was $8.3 \text{ ng/mL} \pm 8.3$ (mean \pm standard deviation) (range 0.3 - 54.3). The mean Gleason score was 6.67 ± 0.83 . The average number of prior biopsies was 2.26 ± 1.06 (range 1 - 6) and the av-

erage number of prior biopsy cores per patient was 24.7 ± 12.1 (range 6 - 77). Median PSA was significantly higher in the non-cancer group compared to the cancer group (8.8 ng/mL vs. 5.3 ng/mL , $p = 0.03$). Median transitional zone volume was also higher in the non-cancer group but was not statistically significant ($p = 0.09$ by prolate ellipse method; $p = 0.06$ by segmentation method). There was no significant difference between the cancer and non-cancer groups in terms of age, race or other types of prostate volumes.

3.1. Volume Measurements

Transrectal ultrasound data was available on 52 patients. The comparison of total prostate volume measured using transrectal ultrasound and MRI (prolate ellipse or segmentation) are summarized in **Table 2**. Mean ultrasound volumes were significantly smaller than MRI volumes, except for the subset of non-cancer patients with ultrasound volumes greater than 30 mL^3 . The comparison of MRI prolate ellipse and segmentation methods are summarized in **Table 2** as well. The prolate ellipse method significantly under-estimates the transitional zone volume and total prostate volume (transitional zone volume:

Table 1. Patient characteristics.

Characteristic		Cancer (n = 45)	Non-cancer (n = 28)	All Subjects (n = 73)	P-value
Age (year)	Mean (SD)	69.4 (10)	69.3 (8.3)	69.3 (9.3)	0.96 ¹
Race	White	35 (77.8)	25 (89.3)	60 (82.2)	0.48 ²
	Black	8 (17.8)	2 (7.1)	10 (13.7)	
N (%)	Hispanic	2 (4.4)	1 (3.6)	3 (4.1)	
PSA (ng/mL)	Median (Q1, Q3)	5.3 (2.7, 8.1)	8.8 (5.2, 11.2)	6.3 (3.6, 9.8)	0.03 ¹
	<2	3 (6.7)	2 (7.1)	5 (6.8)	0.1 ²
N (%)	2 - 4	13 (28.9)	2 (7.1)	15 (20.5)	
	4 - 10	21 (46.7)	15 (53.6)	36 (49.3)	
	≥ 10	8 (17.8)	9 (32.1)	17 (23.3)	
Prostate Volumes (mL^3)	Total Vol _U ³	27.7 (22.2, 40.8)	26.4 (24.1, 59.5)	27.1 (22.4, 42.5)	0.37 ¹
	Transitional Vol _E	16.6 (11.3, 29.6)	24.4 (15.9, 39)	20.2 (11.8, 35.2)	0.09 ¹
	Peripheral Vol _E	16.7 (12.9, 20.2)	16.7 (13, 23.4)	16.7 (12.9, 23)	0.75 ¹
Median (Q1, Q3)	Total Vol _E	35.3 (25.7, 49.7)	42 (31.5, 65)	37.5 (26, 57.1)	0.12 ¹
	Transitional Vol _S	18.5 (13.5, 31.3)	24.4 (17.2, 46.4)	20.1 (14.5, 40.5)	0.06 ¹
	Peripheral Vol _S	17 (15.2, 20.7)	18.7 (14.1, 23.6)	17.1 (14.9, 22.5)	0.5 ¹
	Total Vol _S	38.3 (28.1, 47.4)	44.3 (32.9, 71.4)	39.8 (30.3, 60.2)	0.12 ¹
Gleason grade	<7	24 (53.3)			NA
N (%)	≥ 7	21 (46.7)			

Table 2. Comparison of total prostate volume measured by different approaches and comparison of transitional zone volume, peripheral zone volume and total prostate volume measured by prolate ellipse method vs. segmentation method.

All subjects					
	Statistics	Ultrasound	Prolate ellipse	Segmentation	P-value
ALL	N	52	73	73	
	Median	27.05	37.5	39.8	<0.001
	(Q1, Q3)	(22.4, 42.5)	(26, 57.1)	(30.3, 60.2)	
Vol _U < 30	N	30	30	30	
	Median	23.15	26.2	29.85	<0.001
	(Q1, Q3)	(20.5, 25.6)	(23.6, 33.2)	(26.7, 35.1)	
Vol _U ≥ 30	N	22	22	22	
	Median	44.05	57	57.5	0.02
	(Q1, Q3)	(39.7, 60.4)	(43.8, 81.9)	(45.5, 83.9)	
All subjects (N = 73)					
	Statistics	Prolate ellipse	Segmentation	P-value	
Transitional	Median	20.2	20.1	0.002	
	(Q1, Q3)	(11.8, 35.2)	(14.5, 40.5)		
Peripheral	Median	16.7	17.1	0.18	
	(Q1, Q3)	(12.9, 23)	(14.9, 22.5)		
Total	Median	37.5	39.8	<0.001	

$p = 0.002$ for all subjects; total prostate volume: $p < 0.001$ for all subjects). Prolate ellipse and segmentation methods were similar for peripheral zone volume calculations $p = 0.18$ for all subjects.

3.2. PSA Density

The average PSA in this population was lower in the cancer group than in the benign prostatic hypertrophy group ($p = 0.03$). The descriptive and diagnostic statistics of PSA and PSA density based on transitional zone volume, total prostate volume, and peripheral zone volumes using MRI prolate ellipse or segmentation methods or ultrasound are summarized in **Table 3**. Only the peripheral zone PSA density was significantly different between the BPH and cancer groups, based prolate ellipse or segmentation calculations ($p = 0.03$ for both calculations). The medians of the rest of the biomarkers are not significantly different between cancer and non-cancer groups. All AUCs were below 0.5 indicating all the markers were under-expressed in cancer in this sample.

PSA and PSA densities are also compared between cancer groups, high-grade cancer (Gleason ≥ 7) and low-grade/non-cancer (Gleason score < 7). As shown in **Table 4**, all

markers were significantly higher in the high-grade cancer group compared to low-grade cancer/non-cancer group. The median values of ultrasound PSA density and segmentation transitional zone PSA density were significantly higher in high-grade cancer group compared to non-cancer or low-grade cancer groups. The AUCs for ultrasound PSA density and segmentation transitional zone PSA density were 0.68 (95% CI: 0.52 - 0.83) and 0.67 (95% CI: 0.54 - 0.8), respectively, which were higher, although not significantly different than the AUC for PSA of 0.57 (95% CI: 0.43 - 0.71) (**Figure 2**).

4. Discussion

PSA is a commonly used tool to screen men for possible prostate cancer. While a cutoff of 4.0 ng/mL is frequently used to indicate greater cancer risk, the value often over-diagnoses many men, leading to significant morbidity from biopsies and surgeries [19]. PSA alone has no effect on long-term cancer survival [20,21]. One major hindrance to PSA testing is its lack of specificity. Benign prostatic hypertrophy is known to increase PSA, accounting for up to 85% of cases with a PSA between 4.1 - 10.0 ng/mL [22]. Inflammation can also increase

Table 3. Biomarker characteristics in cancer and non-cancer groups.

	Non-Cancer	Cancer	P-value	AUC (95%CI)
PSA			0.03	0.35 (0.22, 0.48)
N	28	45		
Mean (SD)	9.19 (6.64)	7.75 (9.23)		
Median (Q1, Q3)	8.75 (5.2, 11.2)	5.3 (2.7, 8.1)		
PSAdUS			0.33	0.41 (0.25, 0.57)
N	15	37		
Mean (SD)	0.23 (0.18)	0.21 (0.21)		
Median (Q1, Q3)	0.22 (0.12, 0.27)	0.14 (0.1, 0.28)		
PSAdET			0.17	0.4 (0.27, 0.53)
N	28	45		
Mean (SD)	0.21 (0.2)	0.25 (0.4)		
Median (Q1, Q3)	0.15 (0.11, 0.23)	0.12 (0.07, 0.23)		
PSAdST			0.19	0.41 (0.28,0.54)
N	28	45		
Mean (SD)	0.2 (0.18)	0.21 (0.27)		
Median (Q1, Q3)	0.15 (0.1, 0.25)	0.11 (0.07, 0.24)		
PSAd _{EC}			0.59	0.46 (0.33, 0.59)
N	28	45		
Mean (SD)	0.4 (0.47)	0.48 (0.79)		
Median (Q1, Q3)	0.27 (0.18, 0.47)	0.25 (0.13, 0.55)		
PSAd _{EP}			0.03	0.35 (0.22, 0.48)
N	28	45		
Mean (SD)	0.53 (0.4)	0.55 (0.83)		
Median (Q1, Q3)	0.42 (0.28, 0.67)	0.25 (0.17, 0.47)		
PSAd _{SC}			0.65	0.47 (0.34, 0.6)
N	28	45		
Mean (SD)	0.37 (0.39)	0.41 (0.54)		
Median (Q1, Q3)	0.24 (0.14, 0.48)	0.22 (0.11, 0.5)		
PSAd _{SP}			0.03	0.34 (0.21, 0.47)
N	28	45		
Mean (SD)	0.51 (0.39)	0.45 (0.54)		
Median (Q1, Q3)	0.49 (0.28, 0.58)	0.25 (0.16, 0.42)		

PSA levels. For these reasons, normalizing PSA to prostate volume has been advocated. Kalish first suggested in 1994 to normalize PSA to the transitional zone, as this would normalize PSA values for BPH changes [8].

Kalish showed that PSAd based on transitional zone was the most correlated with the presence of cancer. However, transitional zone PSAd has been refuted by another study PSAd based on transitional zone volume has since been

Table 4. Biomarker characteristics in high-grade cancer and non-cancer or low-grade cancer groups.

	Non-Cancer or low-grade cancer	High-grade cancer(Gleason \geq 7)	P-value	AUC (95% CI)
PSA			0.34	0.57 (0.43, 0.71)
N	52	21		
Mean (SD)	7.74 (6.94)	9.71 (11.09)		
Median (Q1, Q3)	5.8 (3.5, 9.8)	7.3 (5, 8.8)		
PSAd _{US}			0.05	0.68 (0.52, 0.83)
N	37	15		
Mean (SD)	0.2 (0.2)	0.27 (0.18)		
Median (Q1, Q3)	0.14 (0.1, 0.24)	0.24 (0.13, 0.33)		
PSAd _{ET}			0.18	0.6 (0.46, 0.74)
N	52	21		
Mean (SD)	0.2 (0.26)	0.31 (0.48)		
Median (Q1, Q3)	0.12 (0.08, 0.22)	0.18 (0.09, 0.33)		
PSAd _{ST}			0.1	0.62 (0.49, 0.76)
N	52	21		
Mean (SD)	0.19 (0.21)	0.25 (0.28)		
Median (Q1, Q3)	0.11 (0.07, 0.22)	0.17 (0.1, 0.27)		
PSAd _{EC}			0.11	0.62 (0.48, 0.76)
N	52	21		
Mean (SD)	0.39 (0.5)	0.61 (1.01)		
Median (Q1, Q3)	0.24 (0.13, 0.37)	0.35 (0.19, 0.62)		
PSAd _{EP}			0.39	0.56 (0.42, 0.71)
N	52	21		
Mean (SD)	0.5 (0.59)	0.66 (0.92)		
Median (Q1, Q3)	0.3 (0.17, 0.57)	0.38 (0.21, 0.66)		
PSAd _{SC}			0.02	0.67 (0.54, 0.8)
N	52	21		
Mean (SD)	0.35 (0.44)	0.51 (0.59)		
Median (Q1, Q3)	0.19 (0.12, 0.39)	0.33 (0.2, 0.61)		
PSAd _{SP}			0.49	0.55 (0.41, 0.69)
N	52	21		
Mean (SD)	0.45 (0.45)	0.54 (0.57)		
Median (Q1, Q3)	0.32 (0.2, 0.53)	0.34 (0.21, 0.56)		

refuted in another study [9]. There is great variability in determining the transitional zone volumes by transrectal ultrasound [12,13]. MRI provides an accurate depiction of prostate zonal anatomy, and has been used to deter-

mine PSAd in a small number of studies [14-17]. The technique used for the calculation is varied and each sample has been small. While transitional zone PSAd has been shown to be the most accurate parameter at pre-




Figure 2. ROC curves: (a) Detection of prostate cancer. (b) Detection of aggressive prostate cancer. In this sample, all markers were lower in cancer group, therefore, sensitivity was defined as the proportion of cancer cases with biomarker value less than a cut point and specificity as the proportion of controls with biomarker value exceeding a cut point.

dicting Gleason score and presence of cancer, the sensitivity and specificity of such reports is less encouraging.

We attempted to analyze the accuracy of transrectal ultrasound in determining prostate volumes. Similar to prior reports [12], we demonstrated that transrectal ultrasound significantly underestimates prostate volume. The gross underestimation of prostate volume by transrectal ultrasound limits the possible use of transrectal ultrasound based PSAd.

We also attempted to determine if the added volume accuracy of MRI could improve PSAd accuracy. This population was unique in that the average PSA for the cancer patients was actually lower than that of the “control” group. The average PSA in the group (6.3 ng/ml) is higher than expected for the general public. This would be the ideal population where PSAd could be useful, as PSA alone is not specific in accessing cancer risk. Unfortunately, the density normalization was not helpful in determining cancer risk. The only statistically significant PSAd measurements were PSA and peripheral zone PSAd; however, these were inverted from the hypothesized values with the cancer group demonstrating lower averages. The PSAd calculation was useful in determining high-grade malignancy versus low-grade cancer. The majority of prior reports on the usefulness of MRI in PSAd have focused on the showing that MRI PSAd can determine high versus low grade malignancy, but fail to demonstrate their results for cancer sensitivity.

The lack of added benefit for PSAd based on MRI volumes may be due to selection bias. The patient popula-

tion generally referred to MRI in this retrospective study tended to have high PSA values and no cancer to low grade Gleason scores after multiple biopsies. The referral group may reflect a subset of patients that are at the high end of the normal curve of PSA values. The use of MRI based PSAd may be more useful in a screening population; however, this is yet to be determined.

The study is limited by the lack of prostatectomy on most patients. Even in men with prostatectomy, only one individual had prostate volume recorded. Correlation to prostate volume by prostatectomy sample should be performed on future studies. Another limitation is the unknown affect of the presence of an endorectal coil in volume determinations. The prostate is known to deform with the presence of the endorectal coil. Additional trials should be performed in a screening population to determine if PSAd may be helpful in this more standard patient population. PSAd may be helpful in prediction algorithm to be combined with other parameters to assess prostate cancer risk, as suggested by Kubota [16]. This study is useful in that it reports results from a moderate sized sample, tests the added resolution of 3.0 T MRI, and shows cancer sensitivity in addition to high grade cancer differentiation.

The cost of MRI calculated volume is much greater than transrectal ultrasound calculated volume. While the volume measurement is not the sole reason for performing prostate MRI or transrectal ultrasound, the technical fee for a prostate MRI is \$1900, while the transrectal ultrasound technical fee is \$180 at our institution.

In summary, transitional PSA_d by MRI segmentation method and transrectal ultrasound PSA_d positively correlated with aggressive cancer. However, PSA_d was unable to demonstrate a statistically significant difference from PSA for detection of cancer risk in our patient population.

Conflict of interest: Dr. Ian Thompson is a paid consultant for Mission Pharmaceutical, which provides compensation to the University of Texas Health Science Center at San Antonio.

5. References

- [1] J. Hernandez and I. Thompson, "Prostate-Specific Antigen: A Review of the Validation of the Most Commonly Used Cancer Biomarker," *A Cancer Journal for Clinicians*, Vol. 101, No. 5, 2004, pp. 894-904.
- [2] S. Wilson and E. Crawford, "Screening for Prostate Cancer," *Clinical Genitourinary Cancer*, Vol. 3, No. 1, 2004, pp. 21-25. [doi:10.3816/CGC.2004.n.008](https://doi.org/10.3816/CGC.2004.n.008)
- [3] M. Bazinet, A. Meshref, C. Trudel, S. Aronson, F. PÉloquin, M. Nachabe, L. BÉgin and M. Elhilali, "Prospective Evaluation of Prostate-Specific Antigen Density and Systematic Biopsies for Early Detection of Prostatic Carcinoma," *Urology*, Vol. 43, No. 1, 1994, pp. 44-51. [doi:10.1016/S0090-4295\(94\)80260-2](https://doi.org/10.1016/S0090-4295(94)80260-2)
- [4] M. Benson, I. Whang, A. Pantuck, K. Ring, S. Kaplan, C. Olsson and W. Cooner, "Prostate Specific Antigen Density: A Means of Distinguishing Benign Prostatic Hyperplasia and Prostate Cancer," *The Journal of Urology*, Vol. 147, No. 3, 1992, pp. 815-816.
- [5] E. Seaman, M. Whang, C. Olsson, A. Katz, W. Cooner and M. Benson, "Psa Density (Psad). Role in Patient Evaluation and Management," *The Urologic Clinics of North America*, Vol. 20, No. 4, 1993, pp. 653-663.
- [6] B. Djavan, M. Remzi, A. Zlotta, V. Ravary, P. Hammerer, A. Reissigl, P. Dobronski, A. Kaisary and M. Marberger, "Complexed Prostate-Specific Antigen, Complexed Prostate-Specific Antigen Density of Total and Transition Zone, Complexed/Total Prostate-Specific Antigen Ratio, Free-to-Total Prostate-Specific Antigen Ratio, Density of Total and Transition Zone Prostate-Specific Antigen: Results of the Prospective Multicenter European Trial," *Urology*, Vol. 60, No. 4, 2002, pp. 4-9. [doi:10.1016/S0090-4295\(02\)01896-4](https://doi.org/10.1016/S0090-4295(02)01896-4)
- [7] B. Djavan, A. Zlotta, C. Kratzik, M. Remzi, C. Seitz, C. Schulman and M. Marberger, "Psa, Psa Density, Psa Density of Transition Zone, Free/Total Psa Ratio, and Psa Velocity for Early Detection of Prostate Cancer in Men with Serum Psa 2.5 to 4.0 ng/ml," *Urology*, Vol. 54, No. 3, 1999, pp. 517-522.
- [8] J. Kalish, W. Cooner and S. Graham Jr., "Serum Psa Adjusted for Volume of Transition Zone (Psat) Is More Accurate than Psa Adjusted for Total Gland Volume (Psad) in Detecting Adenocarcinoma of the Prostate," *Urology*, Vol. 43, No. 5, 1994, pp. 601-606. [doi:10.1016/0090-4295\(94\)90170-8](https://doi.org/10.1016/0090-4295(94)90170-8)
- [9] D. Lin, M. Gold, S. Ransom, W. Ellis and M. Brawer, "Transition Zone Prostate Specific Antigen Density: Lack of Use in Prediction of Prostatic Carcinoma," *The Journal of Urology*, Vol. 160, No. 1, 1998, pp. 77-82. [doi:10.1016/S0022-5347\(01\)63036-2](https://doi.org/10.1016/S0022-5347(01)63036-2)
- [10] M. Remzi, B. Djavan, R. Wammack, M. Momeni, C. Seitz, B. Erne, M. Dobrovits, S. Alavi and M. Marberger, "Can Total and Transition Zone Volume of the Prostate Determine whether to Perform a Repeat Biopsy?" *Urology*, Vol. 61, No. 1, 2003, pp. 161-166. [doi:10.1016/S0090-4295\(02\)02099-X](https://doi.org/10.1016/S0090-4295(02)02099-X)
- [11] H. Maeda, Y. Arai, S. Ishitoya, K. Okubo, Y. Aoki and T. Okada, "Prostate Specific Antigen Adjusted for the Transition Zone Volume as an Indicator of Prostate Cancer," *The Journal of Urology*, Vol. 158, No. 6, 1997, pp. 2193-2196. [doi:10.1016/S0022-5347\(01\)68193-X](https://doi.org/10.1016/S0022-5347(01)68193-X)
- [12] M. Nathan, K. Seenivasagam, Q. Mei, J. Wickham and R. Miller, "Transrectal Ultrasonography: Why Are Estimates of Prostate Volume and Dimension So Inaccurate," *British Journal of Urology*, Vol. 77, No. 3, 1996, pp. 401-407.
- [13] M. Terris and T. Stamey, "Determination of Prostate Volume by Transrectal Ultrasound," *The Journal of Urology*, Vol. 145, No. 5, 1991, p. 984.
- [14] A. Graser, A. Heuck, B. Sommer, J. Massmann, M. Reiser and U. Mueller-Lisse, "Mri-Based Psa Density and Psa Density of the Transitional Zone Compared with Psa Alone: Correlation with Prostate Cancer Gleason Score," *Journal of Computer Assisted Tomography*, Vol. 30, No. 6, 2006, pp. 891-895. [doi:10.1097/01.rct.0000221947.68016.d1](https://doi.org/10.1097/01.rct.0000221947.68016.d1)
- [15] T. Hoshii, T. Nishiyama, S. Toyabe, K. Akazawa, S. Komatsu, M. Kaneko, N. Hara and K. Takahashi, "Evaluation of Magnetic Resonance Imaging-Based Prostate-Specific Antigen Density of the Prostate in the Diagnosis of Prostate Cancer," *International Journal of Urology*, Vol. 14, No. 4, 2007, pp. 305-310. [doi:10.1111/j.1442-2042.2007.01686.x](https://doi.org/10.1111/j.1442-2042.2007.01686.x)
- [16] Y. Kubota, S. Kamei, M. Nakano, H. Ehara, T. Deguchi and O. Tanaka, "The Potential Role of Prebiopsy Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Detection of Prostate Cancer," *International Journal of Urology*, Vol. 15, No. 4, 2008, pp. 322-326. [doi:10.1111/j.1442-2042.2008.01991.x](https://doi.org/10.1111/j.1442-2042.2008.01991.x)
- [17] U. Mueller-Lisse, U. Mueller-Lisse, S. Haller, P. Schneede, J. Scheidler, N. Schmeller, A. Hofstetter and M. Reiser, "Likelihood of Prostate Cancer Based on Prostate-Specific Antigen Density by Mri: Retrospective Analysis," *Journal of Computer Assisted Tomography*, Vol. 26, No. 3, 2002, pp. 432-437. [doi:10.1097/00004728-200205000-00020](https://doi.org/10.1097/00004728-200205000-00020)
- [18] E. DeLong, D. DeLong and D. Clarke-Pearson, "Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach," *Biometrics*, Vol. 44, No. 3, 1988, pp. 837-845. [doi:10.2307/2531595](https://doi.org/10.2307/2531595)
- [19] I. Thompson, D. Pauler, P. Goodman, C. Tangen, M.

- Lucia, H. Parnes, L. Minasian, L. Ford, S. Lippman and E. Crawford, "Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level \leq 4.0 ng per Milliliter," *New England Journal of Medicine*, Vol. 350, No. 22, 2004, pp. 2239-2321.
[doi:10.1056/NEJMoa031918](https://doi.org/10.1056/NEJMoa031918)
- [20] G. Andriole, E. Crawford, R. Grubb III, S. Buys, D. Chia, T. Church, M. Fouad, E. Gelmann, P. Kvale and D. Reding, "Mortality Results from a Randomized Prostate-Cancer Screening Trial," *The New England Journal of Medicine*, Vol. 360, No. 13, 2009, pp. 1310-1319.
[doi:10.1056/NEJMoa0810696](https://doi.org/10.1056/NEJMoa0810696)
- [21] F. Schroder, J. Hugosson, M. Roobol, T. Tammela, S. Ciatto, V. Nelen, M. Kwiatkowski, M. Lujan, H. Lilja and M. Zappa, "Screening and Prostate-Cancer Mortality in a Randomized European Study," *New England Journal of Medicine*, Vol. 360, No. 13, 2009, pp. 1320-1328.
[doi:10.1056/NEJMoa0810084](https://doi.org/10.1056/NEJMoa0810084)
- [22] W. Catalona, J. Richie, F. Ahmann, M. Hudson, P. Scardino, R. Flanigan, J. DeKernion, T. Ratliff, L. Kavoussi and B. Dalkin, "Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men," *The Journal of Urology*, Vol. 151, No. 5, 1994, pp. 1283-1290.